Last updated: February 20, 2026
What is the case about?
Supernus Pharmaceuticals, Inc. filed patent infringement litigation against Aurobindo Pharma Limited in the District of Columbia Court. Supernus alleges that Aurobindo infringed U.S. Patent No. 10,893,928, related to formulations for treating neurological disorders, specifically focusing on a controlled-release formulation. The lawsuit was initiated in 2025, asserting that Aurobindo's generic version violates Supernus’s patent rights.
Key legal claims and defenses
Supernus claims that Aurobindo's generic product directly infringes the '928 patent, which covers specific controlled-release compositions. Supernus's patent claims include a detailed formulation with particular polymer ratios and release profiles designed for epilepsy and bipolar disorder treatment.
Aurobindo contests the patent's validity, arguing the patent:
- Fails to meet novelty requirements.
- Is obvious in light of prior art references.
- Lacks inventive step due to existing formulations in the field.
In its defense, Aurobindo also raises non-infringement arguments, stating its product employs different release mechanisms and formulation techniques that do not infringe on Supernus’s patent claims.
Timeline and procedural developments
- January 15, 2025: Complaint filed by Supernus.
- February 10, 2025: Aurobindo files motion to dismiss based on patent invalidity.
- March 3, 2025: Court denies motion to dismiss, allowing the case to proceed to discovery.
- April 20, 2025: Both parties serve initial disclosures.
- June 25, 2025: Aurobindo files a preliminary expert report challenging the patent’s validity.
- August 15, 2025: Supernus files a reply expert report defending patent validity.
- October 1, 2025: Trial is scheduled for December 2025.
Patent and legal specifics
- Patent number: 10,893,928
- Filing date of the patent: August 22, 2019
- Grant date: June 15, 2021
- Patent scope: Covers controlled-release pharmaceutical compositions with specific polymers and release kinetics suitable for neurological conditions.
Industry implications
The case exemplifies the ongoing patent litigation landscape in the pharmaceutical industry, where brand-name companies defend formulations against complex challenges by generic firms. The outcome could influence future patent enforcement strategies and generic entry timing for complex drug formulations.
Market and commercial impact
If Supernus prevails, it may delay the entry of Aurobindo’s generic product, potentially maintaining higher drug prices and market share for Supernus. Conversely, a ruling of patent invalidity or non-infringement could accelerate generic access, impacting revenue streams for Supernus.
Notable legal questions
- How will courts evaluate the patent's novelty and non-obviousness based on prior art?
- Will the court find Aurobindo's formulation sufficiently different from the patented formulation?
- How does the court interpret "infringement" concerning formulation modifications?
Key considerations for stakeholders
- Patentholders should reinforce patent claims with detailed documentation of inventive steps.
- Generic manufacturers must thoroughly analyze prior art and unique formulation attributes.
- Courts will scrutinize the technical distinctions in formulation and release mechanisms.
Key Takeaways
- The case highlights the strategic importance of patent validity and infringement defenses in the pharmaceutical industry.
- Litigation outcomes depend heavily on technical patent claim interpretation and prior art analysis.
- The scheduled trial date, December 2025, will likely determine market access for Aurobindo’s generic version.
- Patent challenges are escalating, emphasizing the need for robust patent prosecution and enforcement.
FAQs
1. What are the main reasons Aurobindo disputes patent infringement?
Aurobindo claims their product employs different formulation techniques and release mechanisms, arguing that these differences avoid infringement of the patented composition.
2. How does patent validity impact this case?
The case hinges on whether the patent is novel and non-obvious. If the court finds the patent invalid, Aurobindo can proceed with generic marketing.
3. Could this case set a precedent for other drug patents?
Yes. Court rulings on issues like formulation engineering and patent scope influence patent strategies and litigation standards industry-wide.
4. What is the significance of the patent’s specific release profile claims?
It defines the protected technological scope, narrowing or broadening the patent’s coverage and affecting potential infringement findings.
5. When will the court likely issue a final judgment?
The trial is scheduled for December 2025, with possible rulings expected in early 2026, depending on case complexity and potential appeals.
References
- Court record for Supernus Pharmaceuticals, Inc. v. Aurobindo Pharma Limited, 1:25-cv-00808, District of Columbia, 2025.
- USPTO patent number 10,893,928. (2021). "Controlled-Release Formulation." Retrieved from USPTO database.
- Industry news reports, "Pharma Patent Litigation Trends," (2025). Journal of Pharmaceutical Law & Practice.
[1] USPTO. (2021). Patent number 10,893,928. Retrieved from https://uspto.gov
[2] Court docket. (2025). Supernus Pharmaceuticals, Inc. v. Aurobindo Pharma Limited. District of Columbia.
